Abbott (NYSE:ABT) said today that it plans to acquire mitral heart valve replacement tech developer Cephea Valve Technologies for an undisclosed amount. The Chicago-area healthcare giant backed the Santa Clara, Calif.-based valve company in July 2015 and secured an option to purchase it outright, which it has now chosen to exercise. Cephea is developing mitral valve […]
Cephea Valve Technologies
Abbott drops $250m on Tendyne, backs Cephea in mitral valve play
CEO Miles White proved today that he wasn’t just blowing smoke last week when he said that Abbott (NYSE:ABT) has powder to burn and is ready to use it. Abbott today revealed a pair of investments aimed at building out its presence in the mitral valve replacement market, saying it put another $225 million on top of the […]